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ABSTRACT
Endometrium is the only tissue in the human body subject to cyclic transformations under the influence of ovarian steroid 
hormones. As estradiol and progesterone balance throughout the physiological menstrual cycle changes, so does the ex-
pression of metalloproteinases (MMPs). These endopeptides are responsible for keeping the balance between the process 
of synthesis and degradation of extracellular matrix proteins. Thus, MMP’s take part in sustaining physiological stability of 
the endometrium. A number of MMPs found in the endometrial tissue and their activity is related to menstrual cycle phase. 
This paper is an up-to-date review of literature of Medline database. The search was conducted for key words including 
“matrix metalloproteinases”, “MMPs”, “TIMPs” and “tissue inhibitors of metalloproteinases”. Over 1092 publications regarding 
interdependence and interplay between ovarian hormones and the role of various MMPs and their inhibitors in normal 
endometrial remodelling and in pathological conditions were analysed and critically reviewed. 
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INTRODUCTION
Endometrium is the only tissue in the female body sub-
ject to constant cyclic transformations. The function of hor-
mones, especially estradiol and progesterone, is crucial for 
the proper course of such cyclic transformations. Changes in 
hormone excretion directly influence the release and activity 
of both metalloproteinases (MMPs, matrix metalloprotein-
ases) as well as their tissue inhibitors (TIMPs). 
MMPs are vital for the maintenance of physiological hae-
mostasis, angiogenesis and proper endometrium develop-
ment [1]. Its bioactivity regulates proliferation, endometrial 
cells’ differentiation and decidual transformation. Some 
MMPs are involved in the activation of apoptosis and thus 
the onset of menstrual bleeding [2].
Expression of various MMPs in female endometrium is 
different throughout the menstrual cycle. Most MMPs yield 
maximal expression around menstruation time while in 
proliferative or secretive phase they remain undetectable. 
Expression of some other MMPs in turn remains constant 
throughout the whole menstrual cycle [3]. The course of en-
dometrial transformation, proliferation, secretional changes, 
exfoliation and finally re-growth, as well as coordination of 
such processes is directly dependent on MMPs and their 
inhibitors. A dozen different MMPs are involved and their 
expression is strongly influenced by sex hormones. 
Yet, the interactions between the sex hormones and 
the activity of individual MMPs remain not well understood 
since most of the studies concern a pathophysiological 
role of MMPs while their regulating role in a normal tissue 
is rarely investigated. This review attempts to collect and 
summarize the results of studies that assess the endometrial 
changes in MMPs’ expression in a physiological hormonal 
cycle and in some selected pathological conditions of fe-
male reproductive organs. 
METHODOLOGY
A Medline search for the following MeSH terms and 
key words was performed on January 31st 2017: “MMPs”, 
“matrix metalloproteinases”, “TIMPs” and “tissue inhibi-
tors of metalloproteinases”. From over 1092 publications 
we selected those that concerned the interdependence 
of ovarian hormones on various MMPs and their inhibi-
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tors in normal endometrial remodelling or in pathological 
states. Such works were analysed and critically reviewed. 
MMPs are widely described in various fields of medicine, but 
surprisingly enough only a few studies assessed their role in 
endometrium shedding and remodelling. A more detailed 
cross-check for MeSH terms: “MMPs expression”, “genetic 
factors” and “epigenetic factors” revealed 197 publications 
that investigated regulatory mechanisms responsible for 
changes in cellular membrane and extracellular matrix. Data 
here was analysed with a particular emphasis on processes 
occurring in female reproductive organs — both healthy 
and in pathological conditions. 
The structure and function of matrix 
metalloproteinases and their tissue inhibitors
MMPs are a group of enzymatic proteins with a proteo-
lytic activity and they derive from endopeptidase family. 
In their structure they have a signal peptide responsible 
for a molecular transport through endoplasmic reticulum 
and a catalytic domain with a zinc molecule (Zn2+). This 
domain is responsible for functional proteolytic capacity 
of the enzyme [4].
Transcription genes regulate MMPs activity by three 
means: intracellular production of proenzymes, enzyme 
excretion and its extracellular activation. 
Genes responsible for MMPs synthesis are regulated by 
many factors including steroid hormones, growth factors, 
cytokines and oncogenes [5]. It has been demonstrated that 
secretion of MMP-1, MMP-3 and MMP-9 is stimulated by 
TNF-β and interleukin-1. In contrast, MMP-2 is independent 
of such cytokines [6, 7]. 
MMPs are activated in tissue by proteases including 
plasmine, MMP-3 and MT-MMPs (membrane-type metal-
loproteinases) [8]. Proteolytic activity of MMPs depends on 
the type of tissue, local pH and the activity of MMP inhibitors 
and serine proteases [9]. 
In mature tissues MMPs have usually low concentra-
tions. Their production and expression is increased during 
tissue reorganisation, inflammation or during a healing 
process. Most MMPs are activated outside of the cell by other 
active MMPs or by serine proteases except MMP-11, -14 and 
-28, which can be activated on the inside of the cell [10].
MMPs play an important role in the pathogenesis of 
diseases associated with structural changes of tissues. The 
term “metalloproteinases-dependent diseases” is used in 
various fields to describe such diseases including: multiple 
sclerosis, diabetes mellitus, ovarian and breast cancer or 
endometriosis, all of which share the pathomechanism that 
involves a deregulation of MMPs balance [11].
The activity of MMPs is also regulated by their tissue 
inhibitors (TIMP-1 to TIMP-4). It has been shown that they 
not only regulate MMPs activity, but also play an important 
role in neoplasm growth stimulation, angiogenesis and 
apoptosis. Research on their function and their collateral 
interactions with MMPs is still on-going. 
The molecule of TIMP is built out of two domains that 
form a complex of low molecular weight and small size. 
TIMPs have an inherent ability to bind to the active centre 
of a MMP molecule. The attachment of TIMP’s N-terminal 
domain to the catalytic site of MMP disables the MMP’s ac-
tivity [12]. TIMPs inhibit both: the active forms of MMPs and 
their proenzymes, which translates to a better regulation of 
extracellular matrix. Their activity ensures balance between 
the processes of matrix synthesis and degradation [13].
The two major MMP inhibitors are TIMP-1 and 
TIMP-2. TIMP-1 is a glycoprotein with a molecular weight of 
28 kDa and may be produced by most types of cells. TIMP-2 in 
turn is a soluble protein of 21 kDa synthesised by fibro-
blasts and endothelial cells only. TIMP-1 has a stronger af-
finity to MMP-9, whereas TIMP-2 exhibits selective affinity 
to MMP-2. TIMP-1 binds with inactive MMP-1, -2, -3, -9 while 
TIMP-2 binds with active forms of these MMPs, and also 
with an inactive form of MMP-2 [12]. An imbalance between 
active forms of enzymes and their inhibitors leads to con-
nective tissue degradation. 
Phases of reproductive cycle
The occurrence of menstrual bleeding is normally 
caused by the decrease of circulating steroid hormones as 
their synthesis in the ovaries drops. In vitro studies show 
an important role that estradiol and progesterone have in 
determining the correlation between expression and inhibi-
tion of metalloproteinases’ activity that happens mainly in 
tissues where collagen fibres were disrupted [3]. It has been 
reported that estradiol enhances the inhibitory effect of pro-
gesterone on both release and activity of collagenase [14].
Immunocytochemistry studies have shown that a physi-
ological decrease in progesterone production or cessation 
of its administration in patients increase production and 
activity of some metalloproteinases, but has no influence 
on the expression of their inhibitors [15]. As a result metal-
loproteinases and their tissue inhibitors get out of balance. 
The predominance of active MMPs induces the degradation 
of collagen, which is closely connected with the beginning 
of menstrual bleeding [16]. 
The constriction of spiral arteries induced by prostaglan-
dins causes regional endometrial ischemia and eventually 
arterial wall damage, which results in blood leakage and ex-
foliation of functional endometrial layer. This process starts 
right after the secretory phase and is induced by an active 
proteolysis process regulated by MMPs activity [17]. High 
expression of MMPs in the superficial surface of endome-
trium indicates their initiating role in the degradation of 
arterial wall during menstrual bleeding. Estradiol in contrast 
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controls the structural changes of endometrium, especially 
its growth that begins just after menstrual bleeding. It drives 
the endometrial cell proliferation and angiogenesis. 
Maintaining the balance between proteases and their 
inhibitors expression may play a fundamental role in cases 
of acyclic bleeding caused by numerous reasons including 
hormonal therapy or administration of contraception [2]. 
Paradoxically, MMPs also play a role in stopping of menstrual 
bleeding by influencing function of platelets. It has been 
shown that MMP-1, MMP-2, MMP-9 and MT1-MMP increase 
aggregation of platelets [18]. 
Expression of selected MMPs in relation to menstrual cy-
cle phases and the area of MMPs activity is shown in Table 1.
Collagenase (MMP-1)
The expression of MMP-1 in the stroma is increased dur-
ing the primary menstrual bleeding period and is inversely 
related to sex steroid concentration and their receptors 
in epithelial cells. This applies especially to progesterone 
since the inhibitory effect of estradiol on MMP-1 expres-
sion remains quite weak. It was shown that stromal cells 
were stimulated to synthesize more MMP-1 in the setting 
of low steroid hormones concentration or scarce steroid 
receptors on the epithelial cell surface. This paracrine ef-
fect is mediated by interleukin-1α and by tumour necrosis 
factor-α. Depending on the cycle phase, the expression of 
MMP-1 is restricted to superficial foci of stromal cells or 
extended towards the entire functional layer and correlates 
both with the disruption of fibrillary matrix and with men-
strual bleeding [19]. 
Stromelysin (MMP-3, MMP-10)
MMP-3 shows intensive expression in the stroma directly 
prior to menstruation (26th–28th day of the cycle). During 
the menstruation MMP-3 can be observed in the arteries. It 
degrades collagen type IV found in the basal lamina and 
is expressed in the place of endometrial detachment so it 
may be lost with it [3]. This way the concentration decreases 
along with menstrual bleeding [20]. MMP-10 in turn expres-
sion was identified in stromal cells only during the menstrual 
phase of the reproductive cycle [21].
Gelatinases (MMP-2, MMP-9)
MMP-2 is present in endometrium throughout the whole 
menstrual cycle playing a role in endometrium stabilisa- 
tion [22]. High expression is observed mainly in arteries in 
late secretory phase and in menstrual phase and is nega-
tively correlated with progesterone concentration [20]. A de-
crease in its concentration provokes a cyclic endometrial 
breakdown and onset of menstruation [23]. In vitro studies 
have shown that both MMP-2 synthesis and expression 
(smooth muscle cells of umbilical artery and coronal arteries) 
depends on 17β-estradiol concentration. At low concentra-
tions MMP-2 prevents arteriosclerotic activity but its high 
concentration promotes vessel injury. This effect is inhibited 
by tamoxifen — an estrogen receptor inhibitor. It seems 
that a similar activity might also influence endometrial ves-
sels [24]. This may be the reason why in patients receiving 
tamoxifen we often see thick endometrium with multiple 
vacuoles. MMP-2 also has a vasoconstrictive effect through 
its contribution to endothelin — a peptide important for 
maintenance of vascular homeostasis [25]. Recently it was 
confirmed that MMP-2 activity is increased in patients with 
cervical cancer [26].
A correlation between MMP-2 concentration and steroid 
hormones in serum and peritoneal fluid in women with 
endometriosis has been found. High concentration of es-
tradiol up-regulates MMP-2 while progesterone decreases 
its activity. 
MMP-9 expression in arterioles and stroma is cycle-phase 
dependent [7]. MMP-9 substrates are mainly elastin and col-
lagen IV which is a major component of basal membranes. It 
Table 1. Expression of chosen MMPs and TIMPs in various menstrual cycle phases and their localisation in endometrium.  
According to Freitas S. (1999), Kokorine I. (1996), Marbaix E. (1996)
Premenstrual and menstrual phase
MMP-1 (stroma)
MMP-3 (arteries, late secretory phase only, decreases along with menstrual bleeding) 
MMP-7 (epithelium, late secretory phase)
MMP-8 (stroma)
MMP-9 (stroma, early secretory phase only) 
MMP-10 (menstrual phase only)
MMP-12 (stroma)
Proliferatory phase
MMP-7 (epithelium)
MMP-11 (stroma)
MMP-26 (epithelium)
Doesn’t change during the menstrual cycle
MMP-2 (stroma, arteries, late secretory phase)
MMP-19 (stroma, vascular endothelial and smooth muscle cells)
TIMP-1 (stroma, arteries)
TIMP-2 (stroma, arteries)
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has been concluded that progesterone inhibits MMP-9 ex-
pression and increases TIMP-1 and TIMP-2 expression. The re-
sults of one study indicate that proMMP-9 is activated by MMP-
26, which may influence endometrial tissue turnover [13]. 
Endometrial explant culture has shown that addition of 
estradiol and progesterone did not consistently affect to-
tal MMP-9 release but visibly reduced proMMP-9 [7]. This 
observation may indicate the potential role of hormones 
in regulation and cessation of menstrual bleeding. The 
mechanism of progesterone influence on MMP-9 expres-
sion is unknown. It has been observed that glandular 
MMP-9 production increases with a progesterone increase 
and is maintained when progesterone concentration de-
creases like before menstruation [7]. This observation may 
suggest the involvement of other mechanisms in regulation 
of MMP-9 levels. MMP-9 is highly expressed in endometrial 
glandules and endometrial stromal cells in women with 
levonorgestrel-containing intrauterine system [27]. Interest-
ingly, MMP-9 expression is not detected after the 20th day 
of cycle [28]. Stettner et al. have shown that MMP-9 may 
play an important role in the invasiveness, progression and 
formation of metastases in several types of malignant gy-
naecological tumours [11]. 
Collagenase (MMP-8)  
and metalloelastase (MMP-12)
The expression of mRNAs for MMP-8 and MMP-12 was 
shown only during menstrual phase of the cycle and was 
correlated with the infiltration of functional layer by transient 
immune cells and induced by inflammatory cytokines [1]. 
Matrilysins (MMP-7 and MMP-26)
Matrilysins are the only metalloproteinases with their 
respective mRNAs localized in the epithelium [29]. MMP-7 is 
involved in the degradation of matrix components (i.e. fi-
bronectin and gelatine), adhesive molecules (i.e. E-cadherin 
and pro-alpha defensin) and in the process of apoptosis. These 
changes are followed by the shedding of the functional 
layer of the endometrium and onset of menstruation [22]. 
It has been demonstrated that progesterone treatment 
can suppress directly or indirectly the MMP-7 gene and pro-
tein expression [30]. MMP-7 may also play a role in the patho-
genesis of endometriosis since MMP-7 expression levels 
in the endometrial epithelial cells of patients with deep 
infiltrating endometriosis are significantly higher compared 
to less severe disease [31]. Cervical cancer cells are capable 
of producing large quantities of MMP-7 [26]. 
The other matrilysin — MMP-26 is structurally similar to 
MMP-7 but has a different biological function. Most prob-
ably it takes part in cellular proliferation, development of 
endometrial glands, growth of stroma and angiogenesis in 
preovulatory phase [32]. MMP-26 expression in the endo-
metrium is detected mainly in proliferative phase. During 
secretory phase of the endometrial cycle MMP-26 expres-
sion is low and in contrast to MMP-7 it does not increase 
with the decrease of progesterone concentrations [1]. The 
above-mentioned enzymes are probably not involved in 
endometrial cells apoptosis and endometrium exfoliation. 
MMP activity is controlled by the expression of their respec-
tive genes. Some recent publications investigate the role of 
epigenetic factors in the development of several pathologi-
cal conditions like cancer and immune disorders [33].
Tissue inhibitors (TIMPs)
During early and mid-follicular phase the expression of 
TIMP-1 is predominantly found in the arterioles and capil-
laries while in the early luteal phase in smooth muscle of 
spiral arteries as well. During menstruation TIMP-1 activity 
is abundant in arterioles so to separate necrotic tissue from 
non-necrotic endometrium. The expression of TIMPs in the 
first days of the cycle indicates their involvement in limiting 
the process of tissue exfoliation and the forthcoming endo-
metrium regeneration. Endometrial arterioles have strong 
expression of TIMP-1, whereas the expression of this enzyme 
in glands and stroma throughout the menstrual cycle and 
in the beginning of the cycle is similar [20]. Maintaining 
an appropriate balance between MMPs and TIMPs activities 
is important also for normal trophoblast implantation in 
physiological pregnancy [34]. 
Membrane-type MMPs
MT2-, 3-, 4- and 5-MMP expression, which is minimal dur-
ing menstrual bleeding and maximal in early proliferation 
phase, advocates for its role in angiogenesis and endome-
trial reconstruction [35].
MMP-19 (RASI 1)
MMP-19 expression was found throughout the whole 
menstrual cycle and its vital role in angiogenesis has been 
well documented. The process of creating new vessels is 
closely related to normal endometrial cyclic changes [1].
SUMMARY
Various MMPs can be found in different parts of endome-
trium and their concentrations are cycle dependent. MMPs 
with the highest stromal and peri-arterial activity during 
menstrual bleeding are: MMP-1, MMP-3, MMP-8, MMP-9, 
and MMP-12. The highest expression of MMP-7, MMP-11 and 
MMP-26 in proliferative endometrium indicates their pos-
sible role in endometrial reconstruction and regeneration. 
Their expression is directly and indirectly dependent on pro-
gesterone and estradiol concentrations. MMP-2, MMP-19, 
TIMP-1, TIMP-2 and MT-MMP are expressed throughout 
the whole menstrual cycle and this observation indicates 
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their possible role in physiological endometrial stabiliza-
tion. Knowledge of MMPs sites of synthesis, their role in 
cyclic endometrial transformation and the factors activating 
and inhibiting their expression allows a far better under-
standing of both physiological and pathological conditions 
such as endometriosis or dysfunctional uterine bleeding. 
Further investigation of MMPs and TIMPs interactions with 
the genetic and epigenetic factors that influence signal-
ling pathways may allow to develop new drugs that would 
precisely and more effectively treat women affected by the 
before-mentioned conditions. 
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